OBJECTIVE： To explore the effect of alendronte sodium and vitamin D3 on the T cell immune indexes in patients with different genders and ages with advanced lung cancer. METHODS： 76 patients with advanced lung cancer were divided into non-small cell lung cancer （NSCLC） group （n＝40） and small cell lung cancer （SCLC） group （n＝36）， and another 38 healthy volunteers were control group. Based on palliative care， all patients received Alendronte sodium and vitamin D3 tablet 1 tablet， po， qd， for 1 month. T cell immune indexes （CD4+， CD8+ and Treg levels） in 2 groups before and after treatment， and when volunteers enrolling the control group were compared； and the incidence of adverse reactions were observed. RESULTS： Compared with control group， there were significant differences in CD4+， CD8+， CD4+/CD8+ and Treg levels （P＜0.05）； but there was no significant difference between NSCLC group and SCLC group （P＞0.05）. After treatment， CD4+ and CD4+/CD8+ levels in NSCLC group and SCLC group increased， changes of male were greater than female， CD8+ and Treg levels decreased， changes of male were greater than female， except for CD8+ level in NSCLC group （P＝0.33）， there were significant differences in others （P＜0.05）； CD4+ and CD4+/CD8+ levels in patients ≤50 years old increased more than patients ＞50 years old， CD8+ and Treg levels decreased more than patients ＞50 years old， the differences were statistically significant （P＜0.05）. No obvious adverse reactions were found. CONCLUSIONS： Alendronte sodium and vitamin D3 can effectively improve the T cell immune indexes in patients with advanced lung cancer， especially for male and patients ≤50 years old， which can be considered as conventional adjuvant drugs for patients with lung cancer.